Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00993265 · ClinicalTrials.gov registry record · Phase 2
N-Acetylcysteine for Pediatric Trichotillomania
A Phase 2 study of Trichotillomania and Hair Pulling, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT00993265: Completed Phase 2 study of Trichotillomania and Hair Pulling, sponsored by Yale University.
NCT00993265 is a Phase 2 study of Trichotillomania and Hair Pulling that has completed, run by Yale University. The registered enrollment target is 39 participants, below the 67-participant average among 8 other Trichotillomania trials with a reported enrollment target (42% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00993265, a Phase 2 study of Trichotillomania and Hair Pulling, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
Trichotillomania (hair pulling) has an estimated lifetime prevalence of 1-3%. Children with trichotillomania can experience significant impairment due to peer teasing, avoidance of activities (such as swimming and socializing), difficulty concentrating on school work and medical complications due to pulling behaviors. Despite the fact that trichotillomania has a childhood onset, no randomized, controlled trials have been completed in childhood trichotillomania. Research in adults with trichotillomania has demonstrated that most commonly currently prescribed treatment for trichotillomania, (pharmacotherapy with selective serotonin reuptake inhibitors) is ineffective in treating this condition. By contrast, randomized controlled trials in adults have suggested the efficacy of N-acetylcysteine as well as behavioral treatments such as Habit Reversal Therapy. The goal of this trial is to determine the efficacy of N-Acetylcysteine for pediatric trichotillomania. N-Acetylcysteine is a glutamate modulating agent, with a fairly benign side-effect profile.
Primary Outcome
The Massachusetts General Hospital - Hairpulling Scale (MGH-HPS) is a 7-question scale that measures the severity of hair pulling. The scale ranges from 0-28. The higher the score, the more severe the hairpulling.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG N-Acetylcysteine
Study Locations (1)
Connecticut
- Yale Child Study Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2009-10 |
| Est. Completion | 2014-03 |
| Phase | Phase 2 |
What the finished NCT00993265 record still lists
NCT00993265 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 67-participant average among 8 other Trichotillomania trials with a reported enrollment target (42% lower).
The record links to 2 conditions, with Trichotillomania appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00993265 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT00993265 about?
NCT00993265 is a clinical study titled "N-Acetylcysteine for Pediatric Trichotillomania". Trichotillomania (hair pulling) has an estimated lifetime prevalence of 1-3%. Children with trichotillomania can experience significant impairment due to peer teasing, avoidance of activities (such as swimming and socializing), difficulty concentrating on school work and medical complications due to...
What is the current status of trial NCT00993265?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2009-10. Estimated completion is 2014-03.
What conditions does trial NCT00993265 study?
This clinical trial studies the following conditions: Trichotillomania, Hair Pulling.
What interventions are being tested in trial NCT00993265?
The interventions under investigation include: Placebo (DRUG), N-Acetylcysteine (DRUG).
Who is sponsoring clinical trial NCT00993265?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00993265 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Trichotillomania
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00993265's enrollment target sits among peer trials
39 4th of 8 higher than 5 of 8 other Trichotillomania trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Trichotillomania trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study in Patients With Trichotillomania
COMPLETED · Phase 2
-
Technology Assisted Treatment of Trichotillomania: Open Trial
RECRUITING · NA
-
Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals
ACTIVE NOT RECRUITING · NA
-
Cognitive Behavioral Treatment of Pediatric Trichotillomania
COMPLETED · NA
-
Response Inhibition Training for Individuals With Trichotillomania
COMPLETED · NA
-
Cognitive Behavioral Therapy for Trichotillomania
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia